Latigo Biotherapeutics, Inc.

What they do

Latigo discovers and develops oral small-molecule inhibitors of the NaV1.8 sodium channel for pain. Its lead program, onzotrigine, targets moderate-to-severe acute pain, while LTG-321 is in a Phase 2 trial in osteoarthritis of the knee and LTG-418 is an earlier-stage next-generation NaV1.8 inhibitor. The company has no approved products and funds operations from equity capital.

Revenue drivers

• Onzotrigine (NaV1.8 inhibitor for acute pain) — Lead clinical-stage program; no product revenue today, with value contingent on Phase 3 success and regulatory approval.
• LTG-321 (NaV1.8 inhibitor for chronic pain) — Phase 2 osteoarthritis-of-the-knee candidate; no revenue today and earlier-stage than onzotrigine.
• LTG-418 and discovery pipeline — Preclinical next-generation NaV1.8 inhibitor plus other ion channel modulators; no revenue today.
• Equity financing — Currently the sole source of funds, including a $397.4 million gross upsized IPO completed in August 2026.

Recent performance

Latigo reported no product revenue and remains a clinical-stage company. As of June 30, 2026, it had total assets of $64.8 million, total liabilities of $52.3 million, cash and equivalents of $55.0 million, and shareholder equity of negative $276.1 million. The company declared no dividends in 2025. In August 2026, it completed an upsized IPO raising gross proceeds of $397.4 million, including full exercise of the underwriters' option.

Strategy

Management is focused on advancing onzotrigine into Phase 3, with a planned randomized, double-blind, placebo-controlled bunionectomy trial and a single-arm, open-label safety trial in the second half of 2026. It also initiated a Phase 2 crossover trial of LTG-321 in approximately 120 knee osteoarthritis patients, conducted at multiple sites in Denmark. It completed 14-day non-GLP toxicology studies for LTG-418 in rats and non-human primates and continues discovery of additional ion channel modulators. The company says its IPO proceeds plus existing cash are expected to fund operations into 2029, and it appointed Naomi Lowy, M.D., as senior vice president of global regulatory affairs.

Risks

• Clinical and regulatory failure — Onzotrigine, LTG-321 and LTG-418 are unapproved, and Phase 3 or Phase 2 failures would delay or eliminate any future product revenue.
• No product revenue — Latigo has no approved products and no product revenue today, so operations depend entirely on external financing.
• Accumulated deficit and negative equity — Shareholder equity was negative $276.1 million at June 30, 2026, reflecting cumulative losses and redeemable convertible preferred stock.
• Cash runway and financing risk — Cash was $55.0 million at June 30, 2026, before the August 2026 IPO proceeds, and future trials may require additional capital if costs exceed plans.

Outlook

Management expects to initiate the onzotrigine Phase 3 bunionectomy and open-label safety trials in the second half of 2026, with topline results expected in the second half of 2027. It also expects topline results from the LTG-321 Phase 2 osteoarthritis trial in the second half of 2027. The company states that IPO proceeds plus existing cash should fund operations into 2029.